| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/18/2003 | US20030175346 Comprises a single-layer compressed core containing drug surrounded by a water permeable layer having a passageway, hydroxyethylcellulose, and osmagent |
| 09/18/2003 | US20030175345 Isoflavone composition for oral delivery |
| 09/18/2003 | US20030175344 Comprising diuretic, beta blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, calcium channel blocker, lipid-regulating agent, platelet function altering agent, serum homocysteine lowering agent |
| 09/18/2003 | US20030175343 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 09/18/2003 | US20030175342 Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate |
| 09/18/2003 | US20030175341 High viscosity cellulosic ether and drug |
| 09/18/2003 | US20030175340 Antiulcer agents (H2-antagonists such as ranitidine and cimetidine); for treating osteoporosis |
| 09/18/2003 | US20030175339 Formed by direct compression; friability |
| 09/18/2003 | US20030175338 Formulations of atorvastatin stabilized with alkali metal additions |
| 09/18/2003 | US20030175337 For treatment of thyroid disorders; hormone replacement therapy |
| 09/18/2003 | US20030175336 Soft tablet containing high molecular weight polyethylene oxide |
| 09/18/2003 | US20030175335 Pectin film compositions |
| 09/18/2003 | US20030175334 Phospholipid bodies and use thereof in medical treatment |
| 09/18/2003 | US20030175333 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
| 09/18/2003 | US20030175331 Pressure sensitive adhesive comprising isoprene-styrene block copolymer/tackifier resin and diclofenac sodium |
| 09/18/2003 | US20030175330 Transdermal therapeutical system with a reduced tendency of the active substance to crystallize |
| 09/18/2003 | US20030175329 Semisolid topical hormonal compositions and methods for treatment |
| 09/18/2003 | US20030175328 Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
| 09/18/2003 | US20030175326 Palatable controlled-release formulations for companion animals |
| 09/18/2003 | US20030175324 For controlled/sustained release; corneal allograft therapy; age-related macular degeneration |
| 09/18/2003 | US20030175321 Inorganic shaped bodies and methods for their production and use |
| 09/18/2003 | US20030175317 Multiple emulsions |
| 09/18/2003 | US20030175315 Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same |
| 09/18/2003 | US20030175313 Preparation of sterile stabilized nanodispersions |
| 09/18/2003 | US20030175309 Adjuvants for use in vaccines |
| 09/18/2003 | US20030175308 Adjuvants for use in vaccines |
| 09/18/2003 | US20030175299 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections; stable oil-in-water emulsions, side effect reduction |
| 09/18/2003 | US20030175298 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections |
| 09/18/2003 | US20030175259 Use of corneal hardening agents in enzymeorthokeratology |
| 09/18/2003 | US20030175256 Allografts comprising undifferentiated fetal skin cells integrated within collagen matrix |
| 09/18/2003 | US20030175239 Protein crystals are encapsulated within a matrix of a biocompatible polymeric carrier; enhance preservation of the native biologically active tertiary structure of the protein, creates reservoir for slow release of protein when needed |
| 09/18/2003 | US20030175221 Cosmetic and skin care formulation containing oil phase, water phase, microfine particles with specific particle size, display both hydrophilic and lipophilic properties, an electrolyte and at most 0.5% by weight of emulsifier. |
| 09/18/2003 | US20030175214 Free-flowing fine particle mixtures comprising carrier particles, active drug particles and stabilizer particles, for respiratory system disorders; medical equipment |
| 09/18/2003 | US20030175213 Nasal solution containing a broad spectrum microbicide and a method for its use |
| 09/18/2003 | US20030175206 Administering large liposomes to retend radioactive decay intermediates |
| 09/18/2003 | US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group |
| 09/18/2003 | US20030175187 Process and apparatus for producing inhalable medicaments |
| 09/18/2003 | US20030173219 Devices and formulations |
| 09/18/2003 | US20030172924 Medicament storage and delivery devices |
| 09/18/2003 | CA2671976A1 Methods of inducing terminal differentiation |
| 09/18/2003 | CA2478685A1 Ophthalmic solutions containing tetrazole derivatives |
| 09/18/2003 | CA2478684A1 Dispersed solid-containing complex carbohydrate |
| 09/18/2003 | CA2478514A1 A system for the controlled release of active ingredients |
| 09/18/2003 | CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes |
| 09/18/2003 | CA2478121A1 Antibiotic composition |
| 09/18/2003 | CA2477982A1 Methods for entrapment of bioactive agent in a liposome or lipid complex |
| 09/18/2003 | CA2477979A1 An inhalation system for treatment of intracellular infections |
| 09/18/2003 | CA2477701A1 Controlled release dosage forms |
| 09/18/2003 | CA2477675A1 Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| 09/18/2003 | CA2477393A1 Ibuprofen solution for hard shell capsules |
| 09/18/2003 | CA2477329A1 Controlled delivery patch of active ingredient |
| 09/18/2003 | CA2475738A1 Activated protein c formulations |
| 09/18/2003 | CA2474613A1 Sustained release drug formulations containing a carrier peptide |
| 09/18/2003 | CA2472782A1 Materials containing multiple layers of vesicles |
| 09/17/2003 | EP1344533A1 Pharmaceutical compositions comprising mannose binding lectin |
| 09/17/2003 | EP1344523A1 Ibuprofen solution for hard gelatin capsules |
| 09/17/2003 | EP1344522A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
| 09/17/2003 | EP1344521A1 Procedure for reconstitution of lyophilized proteins |
| 09/17/2003 | EP1344520A1 Microparticles and method for their production |
| 09/17/2003 | EP1344518A2 Cosmetic and pharmaceutical compositions containing oxyalkylated polyglycerol esters |
| 09/17/2003 | EP1344517A1 Stable dispersion concentrates |
| 09/17/2003 | EP1344516A1 Antioxidative composition |
| 09/17/2003 | EP1344458A1 Probiotic delivery system |
| 09/17/2003 | EP1343818A1 Modified tachykinin receptors |
| 09/17/2003 | EP1343811A1 Methods for preparing purified lipopeptides |
| 09/17/2003 | EP1343596A1 Surface modification process |
| 09/17/2003 | EP1343592A1 Electrostatic application of powder material to solid dosage forms in an electric field |
| 09/17/2003 | EP1343581A2 Instant water dissolvable encapsulate and process |
| 09/17/2003 | EP1343550A1 Metered dose inhaler for salmeterol xinafoate |
| 09/17/2003 | EP1343548A2 Method and apparatus for delivery of therapeutic from a delivery matrix |
| 09/17/2003 | EP1343542A2 Carrier with solid fibrinogen and solid thrombin |
| 09/17/2003 | EP1343530A1 Oral pharmaceutical composition containing a block copolymer |
| 09/17/2003 | EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 09/17/2003 | EP1343521A2 Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations |
| 09/17/2003 | EP1343518A2 Stabilized inteferon compositions |
| 09/17/2003 | EP1343512A1 Injectable solution with anti-inflammatory effect and process for manufacturing the same |
| 09/17/2003 | EP1343511A1 Shark meat extract |
| 09/17/2003 | EP1343508A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 09/17/2003 | EP1343504A2 Pharmaceutical formulation of gepirone for oral administration |
| 09/17/2003 | EP1343502A2 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 09/17/2003 | EP1343492A2 Treatment of mucositis |
| 09/17/2003 | EP1343485A2 Lipid-based nitric oxide donors |
| 09/17/2003 | EP1343484A2 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv |
| 09/17/2003 | EP1343483A2 Transdermal system containing a novel high potency progestagen |
| 09/17/2003 | EP1343482A2 Prolamin-based sustained-release compositions and delayed-onset compositions |
| 09/17/2003 | EP1343481A2 Process for the preparation of a fast dissolving dosage form |
| 09/17/2003 | EP1343480A2 Induced phase transition method for the production of microparticles containing hydrophobic active agents |
| 09/17/2003 | EP1343479A2 Aerogel powder therapeutic agents |
| 09/17/2003 | EP1343478A2 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 09/17/2003 | EP1343477A2 Treatment of inoperable tumors by stereotactic injection of microspheres |
| 09/17/2003 | EP1343476A2 Preparation of large liposomes by infusion into peg |
| 09/17/2003 | EP1343475A2 Self forming, thermodynamically stable liposomes and their applications |
| 09/17/2003 | EP1343474A2 Intraocular irrigating solution having improved flow characteristics |
| 09/17/2003 | EP1343473A1 Pharmaceutical dronedarone composition for parenteral administration |
| 09/17/2003 | EP1343472A2 Thixotropic nasal spray |
| 09/17/2003 | EP1343455A1 Expanded perborate salt, use, and method of production |
| 09/17/2003 | EP1343450A1 Remineralising dental adhesive film |
| 09/17/2003 | EP1343444A2 Solution for removing cataracts via liquefracture |
| 09/17/2003 | EP1343372A2 Pulmonary delivery of polyene antifungal agents |
| 09/17/2003 | EP1207875B1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |